Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHIBOT II
2024-515028-35-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in osteoarthritis (OA) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change from baseline in base-of-thumb pain at 6 months. Planned start Jan 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-515028-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515028-35-00.